SK bioscience Earns ‘A’ Rating in KCGS ESG Assessment for Fourth Consecutive Year 2025.11.19

IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive par... 2025.11.05

SK bioscience strengthens global vaccine partnerships to expand R&D pipeline competitiveness 2025.10.29

SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP51... 2025.10.15

SK bioscience Announces Start of RSV Preventive Antibody Administration for 2025-2026 Season 2025.10.02